<DOC>
	<DOCNO>NCT02259881</DOCNO>
	<brief_summary>To compare placebo anticoagulant activity three dosage BIBT 986 parameter coagulation , platelet activation inflammation model tissue factor trigger activation coagulation system ; examine safety BIBT 986 setting</brief_summary>
	<brief_title>Effect BIBT 986 Followed BIBT 986 Given IV Infusion Tissue Factor Triggered Coagulation Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Thromboplastin</mesh_term>
	<criteria>Healthy male subject determine screening procedure Signed write informed consent form accordance good clinical practice ( GCP ) local legislation available Age ≥ 18 ≤ 40 year Body mass index : BMI ≥ 18 ≤ 29.9 kg/m2 Normal finding medical history physical examination unless investigator consider abnormality clinically irrelevant Normal laboratory parameter unless investigator consider abnormality clinically irrelevant Any find medical examination ( include blood pressure , pulse rate , ECG , laboratory parameter ) deviate normal clinical relevance History current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunologic , autoimmune , hormonal disorder , diseases central nervous system ( epilepsy ) , psychiatric disorder Symptoms clinically relevant illness 3 week first trial day History orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History allergy / hypersensitivity ( include drug allergy ) deem relevant trial judge investigator History bleed disorder include prolonged habitual bleeding familial bleeding disorder haematological disease cerebral bleeding ( e.g . car accident ) commotio cerebri Hereditary deficiency protein C S , mutation factor V ( Leiden ) , know abnormality affect coagulation , fibrinolysis , platelet function Platelet count &lt; 150000/μL Any ECG value outside reference range clinical relevance ( QRS interval &gt; 110 m QTcB ( QT interval Bazett correction ) &gt; 450 m obligatory exclusion criterion ) Intake drug long halflife ( &gt; 24 hour ) within 1 month prior administration Use drug might influence result trial within 10 day prior administration trial Participation another trial investigational drug within 2 month prior administration trial Participation LPS trial within last six week Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) inability refrain smoke study day Concurrent history drug , alcohol , tobacco coffee / tea / cola abuse Blood donation within 1 month prior administration trial Excessive physical activity within 5 day prior administration trial Seropositivity hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) , HIV 1 , HIV 2 antibody Weight 95 kg</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>